(Unlearned) lessons from John Graunt and Kenneth Rothman: A "CLASSic" example

Guardado en:
Detalles Bibliográficos
Publicado en:Clinical Therapeutics vol. 25, no. 11 (Nov 2003), p. 2891
Autor principal: Arellano, Felix M.
Autor Corporativo: Class
Otros Autores: Castellsague, Jordi
Publicado:
Elsevier Limited
Materias:
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

MARC

LEADER 00000nab a2200000uu 4500
001 1032773064
003 UK-CbPIL
022 |a 0149-2918 
022 |a 1879-114X 
024 7 |a 10.1016/S0149-2918(03)80341-7  |2 doi 
035 |a 1032773064 
045 2 |b d20031101  |b d20031130 
084 |a 14693312 
084 |a 170329  |2 nlm 
100 1 |a Arellano, Felix M. 
110 2 |a Class 
245 1 |a (Unlearned) lessons from John Graunt and Kenneth Rothman: A "CLASSic" example 
260 |b Elsevier Limited  |c Nov 2003 
513 |a FLA Commentary Journal Article 
520 3 |a   This commentary reviews the work of John Graunt and Kenneth J. Rothman on statistical significance and the need for prespecification of study end points. The authors argue that it is dangerous to substitute oversimplifications based exclusively on whether a result has reached statistical significance for a rational process of causal inference. An example is given based on the Celecoxib Lonngterm Arthritis Safety Study.   This commentary reviews the work of John Graunt and Kenneth J. Rothman on statistical significance and the need for prespecification of study end points. The authors argue that it is dangerous to substitute oversimplifications based exclusively on whether a result has reached statistical significance for a rational process of causal inference. An example is given based on the Celecoxib Long-term Arthritis Safety Study. 
650 2 2 |a Anti-Inflammatory Agents, Non-Steroidal  |x adverse effects 
650 2 2 |a Data Interpretation, Statistical 
650 2 2 |a Endpoint Determination 
650 1 2 |a Epidemiologic Methods 
650 2 2 |a Epidemiologic Research Design 
650 2 2 |a Humans 
650 2 2 |a Peptic Ulcer  |x chemically induced 
650 2 2 |a Randomized Controlled Trials as Topic 
700 1 |a Castellsague, Jordi 
773 0 |t Clinical Therapeutics  |g vol. 25, no. 11 (Nov 2003), p. 2891 
786 0 |d ProQuest  |t Healthcare Administration Database 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/1032773064/abstract/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/1032773064/fulltext/embedded/6A8EOT78XXH2IG52?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/1032773064/fulltextPDF/embedded/6A8EOT78XXH2IG52?source=fedsrch